Werewolf Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(14.2%),Peter Kolchinsky(14.2%), etc.
Werewolf Therapeutics | 10-Q: Quarterly report
Werewolf Therapeutics | 8-K: Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Werewolf Therapeutics | ARS: Annual Report to Security Holders
Werewolf Therapeutics | DEFA14A: Others
Werewolf Therapeutics | DEF 14A: Definitive information statements
Werewolf Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Werewolf Therapeutics | 10-K: Annual report
Werewolf Therapeutics | 8-K: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Werewolf Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(15.2%),Peter Kolchinsky(15.2%), etc.
Werewolf Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFM Health Sciences, LP(9.6%),PFM Health Sciences GP, LLC(9.6%), etc.
Werewolf Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BANK OF AMERICA CORPORATION(5.8%)
Werewolf Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(5.35%),David Rosen(5.35%)
Werewolf Therapeutics | 8-K: Current report
Werewolf Therapeutics | 424B5: Prospectus
Werewolf Therapeutics | 8-K: Current report
Werewolf Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Atkins Michael B.
Werewolf Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Atkins Michael B.
Werewolf Therapeutics | 8-K: Current report
Werewolf Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Trost Timothy W.
No Data